MARKET

ALT

ALT

Altimmune
NASDAQ
1.330
-0.080
-5.67%
After Hours: 1.360 +0.03 +2.26% 19:55 11/20 EST
OPEN
1.370
PREV CLOSE
1.410
HIGH
1.460
LOW
1.320
VOLUME
4.06M
TURNOVER
--
52 WEEK HIGH
6.44
52 WEEK LOW
1.320
MARKET CAP
258.80M
P/E (TTM)
-1.8552
1D
5D
1M
3M
1Y
5Y
1D
Altimmune Buy Rating Maintained with $20 Price Target as Pemvidutide Shows Promise in AUD and MASH
TipRanks · 4d ago
Altimmune Is Maintained at Outperform by Evercore ISI Group
Dow Jones · 5d ago
Altimmune Price Target Cut to $14.00/Share From $17.00 by Evercore ISI Group
Dow Jones · 5d ago
Evercore ISI Group Maintains Outperform on Altimmune, Lowers Price Target to $14
Benzinga · 5d ago
Weekly Report: what happened at ALT last week (1109-1113)?
Weekly Report · 5d ago
Altimmune Price Target Cut to $11.00/Share From $13.00 by B. Riley Securities
Dow Jones · 11/13 14:29
B. Riley Securities Reiterates Buy on Altimmune, Lowers Price Target to $11
Benzinga · 11/13 14:19
Altimmune price target lowered to $11 from $13 at B. Riley
TipRanks · 11/13 13:37
More
About ALT
Altimmune, Inc. is a late clinical-stage biopharmaceutical company. The Company is developing novel therapies for serious liver diseases. Its lead product candidate, pemvidutide (formerly ALT-801), is a balanced 1:1 glucagon/GLP-1 dual receptor agonist in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD) and alcohol-associated liver disease (ALD). The activation of glucagon receptors results in direct effects on the liver, including reductions in liver fat, inflammation and fibrosis, whereas the activation of GLP-1 receptors mediates suppression of appetite and reduction of cravings as well as metabolic effects such as weight loss. It has completed phase II development of pemvidutide. It also develops and commercializes surfactant-functionalized (EuPort domain) incretin-based peptide therapeutics, including (GLP-1-glucagon)/oxyntomodulin, and variants.

Webull offers Altimmune Inc stock information, including NASDAQ: ALT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ALT stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ALT stock methods without spending real money on the virtual paper trading platform.